Researchers Discover Clues About PML Infection
Main Category: Multiple SclerosisArticle Date: 11 Sep 2009 - 1:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
2.89 (9 votes) |
| Healthcare Prof: |  |
1 (4 votes) |
Research published today in the New England Journal of Medicine has described how progressive multifocal leukoencephalopathy (PML) infection may occur in people taking Tysabri, a drug licensed for use in relapsing remitting multiple sclerosis (MS).
PML is a serious and often fatal infection of the brain that is estimated to occur in approximately one in 1,000 people taking Tysabri over the course of 18 months.
So far 13 cases of PML have been reported worldwide in people taking Tysabri and research is focused on developing ways of predicting and preventing PML.
Source
Multiple Sclerosis Society
Visit our multiple sclerosis section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/163604.php>
APA
http://www.medicalnewstoday.com/releases/163604.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
